tbuckley/cabot-search huggingface dataset:
Adjuvant oxaliplatin plus S-1 (SOX) with concurrent radiotherapy versus SOX alone for gastric cancer with D2 lymph node dissection and high risk factors: a randomized phase III trial
Authors: X. Wang, Y. Shen, Q. Li, M. Qiu, Z. Li, J. Liu, H. Gou, Y. Yang, D. Cao, C. Yi, D. Luo, H. Zhu, Z. Zhou, S. Tan, W. Wang, X. Ye, X. Su, F. Xu, F. Bi
Journal: Annals of Oncology (2017)
GW28-e0241 Effects of Trimetazidine on Cardiac Function of Acute Myocardial Infarction Patients in China: A Meta-analysis
Authors: Hongyuan Bai, Jie Deng, Songlin Zhang, Jin Wei, Anqi Song, Zhenhua Han, Yajuan Ni, Qiangsun Zheng
Journal: Journal of the American College of Cardiology (2017)
The dopaminergic reward system underpins gender differences in social preferences
Authors: Alexander Soutschek, Christopher J. Burke, Anjali Raja Beharelle, Robert Schreiber, Susanna C. Weber, Iliana I. Karipidis, Jolien ten Velden, Bernd Weber, Helene Haker, Tobias Kalenscher, Philippe N. Tobler
Journal: Nature Human Behaviour (2017)
Safety and feasibility of consolidation pembrolizumab following concurrent chemoradiation for unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN14-179.
Authors: Greg Andrew Durm, Cynthia Johnson, Shadia Ibrahim Jalal, Ahad Ali Sadiq, Salma Jabbour, Robin Zon, Goetz H. Kloecker, Karen L. Reckamp, William B. Fisher, Nasser H. Hanna
Journal: Journal of Clinical Oncology (2017)

8523 Background: The standard of care for unresectable stage III NSCLC is concurrent chemorad. Following treatment, the risk of radiation pneumonitis is greatest at 1-3 mo. Pneumonitis risk increases with consolidation chemotherapy. A previous trial by our group (Hanna et al, JCO 2008) of consolidation docetaxel showed 80.8% completed 3 planned cycles of chemo with a grade 3-5 pneumonitis rate of 9.6% and 1 death. PD-1 inhibitors are also associated with an increased risk of pneumonitis in the metastatic setting. We conducted a phase II trial of consolidation pembro initiated 1-2 mo after concurrent chemorad, a period during which pts are at high risk of developing pneumonitis. Methods: Pts with stage III NSCLC who completed chemorad with either carbo/paclitaxel, cis/etop, or cis/pemetrexed plus 59-66.6 Gy of radiation and had no PD received pembro 200mg IV q3wk for up to 1 yr. Primary endpoint is time to metastatic disease. The objective of the study is to evaluate both safety and efficacy, and here we report preliminary safety and feasibility results. Evaluable pts for this analysis had ≥3 mo of f/u or went off study due to PD, toxicity, or death &lt; 3 mos after initiation of pembro. Results: 93 pts enrolled. Median age 67 (range 46-84), 59 (63.4%) were male. 87 (93.5%) were former or current smokers. 68 (73.1%) received carbo/pac, 24 (25.8%) received cis/etop, and 1 received cis/pemetrexed. SqCC (n = 41), non-SqCC (n = 43), NSCLC NOS (n = 8), mixed (n = 1). IIIA (n = 56), IIIB (n = 37). At the time of analysis, 83 of 93 pts were evaluable. 66 of 83 (79.5%) received ≥ 3 mo of pembro. 17 (20.5%) pts developed any grade pneumonitis with 14 of 17 occurring in the first 12 wks (median 9 wks). Only 3 (3.6%) pts developed grade 3-5 pneumonitis related to pembro. There was 1 pneumonitis-related death and a second death from respiratory failure possibly related to pembro. Conclusions: This early report indicates that most patients can safely receive consolidation pembro within 1-2 mo of completing chemorad. The incidence of serious pneumonitis during the first 3 mo of treatment appears low. Updated safety data on all 93 pts will be presented at the ASCO meeting. Clinical trial information: NCT02343952.
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
Authors: J. Cortes Castan, Z. Guo, V. Karantza, G. Aktan
Journal: Annals of Oncology (2017)
A phase 1/2 study on safety of rovalpituzumab tesirine in combination with nivolumab or nivolumab + ipilimumab in small cell lung cancer
Authors: C. Scripture, G. Selvaggi, I. Lakatos, K. Boynton, S. Lally, T.H. Han, S.L. Peng, S.J. Dylla
Journal: Annals of Oncology (2017)
Lactate Promotes Synthetic Phenotype in Vascular Smooth Muscle Cells
Authors: Libang Yang, Ling Gao, Thomas Nickel, Jing Yang, Jingyi Zhou, Adam Gilbertsen, Zhaohui Geng, Caitlin Johnson, Bernice Young, Craig Henke, Glenn R. Gourley, Jianyi Zhang
Journal: Circulation Research (2017)

The phenotypes of vascular smooth muscle cells (vSMCs) comprise a continuum bounded by predominantly contractile and synthetic cells. Some evidence suggests that contractile vSMCs can assume a more synthetic phenotype in response to ischemic injury, but the mechanisms that activate this phenotypic switch are poorly understood.To determine whether lactate, which increases in response to regional ischemia, may promote the synthetic phenotype in vSMCs.Experiments were performed with vSMCs that had been differentiated from human induced pluripotent stem cells and then cultured in glucose-free, lactate-enriched (L+) medium or in standard (L-) medium. Compared with the L- medium, the L+ medium was associated with significant increases in synthetic vSMC marker expression, proliferation, and migration and with significant declines in contractile and apoptotic activity. Furthermore, these changes were accompanied by increases in the expression of monocarboxylic acid transporters and were generally attenuated both by the blockade of monocarboxylic acid transporter activity and by transfection with iRNA for NDRG (N-myc downstream regulated gene). Proteomics, biomarker, and pathway analyses suggested that the L+ medium tended to upregulate the expression of synthetic vSMC markers, the production of extracellular proteins that participate in tissue construction or repair, and the activity of pathways that regulate cell proliferation and migration. Observations in hypoxia-cultured vSMCs were similar to those in L+-cultured vSMCs, and assessments in a swine myocardial infarction model suggested that measurements of lactate levels, lactate-dehydrogenase levels, vSMC proliferation, and monocarboxylic acid transporter and NDRG expression were greater in the ischemic zone than in nonischemic tissues.These results demonstrate for the first time that vSMCs assume a more synthetic phenotype in a microenvironment that is rich in lactate. Thus, mechanisms that link glucose metabolism to vSMC phenotypic switching could play a role in the pathogenesis and treatment of cardiovascular disease.
Mutant KIT translocates into the nucleus and induces NFKBIB expression that leads to KIT expression in imatinib-resistant gastrointestinal stromal tumors
Authors: Y-S. Hsueh, H.H. Chang, Y-S. Shan, H.S. Sun, J.A. Fletcher, C-F. Li, L-T. Chen
Journal: Annals of Oncology (2017)
Desarrollo de una red electrónica europea sobre enfermedades transmisibles: El programa IDA-HSSCD
Authors: J Weinberg, H Nohynek, J Giesecke
Journal: Eurosurveillance (1997)

El desarrollo de la Union Europea (UE), un bloque de comercio multinacional dentro del cual se permite la libre circulacion de mercancias y personas, ha incrementado la dificultad de la vigilancia de las enfermedades transmisibles asociadas a los viajes y al comercio internacional. Como resultado, se han desarrollado varias colaboraciones internacionales para la vigilancia en los paises de la UE. Dichas colaboraciones han tenido exito en la identificacion de brotes que han afectado a mas de un pais (1-4).
Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients
Authors: D. Bixby, C.E. Vigil, J. Jurcic, R. Cook, M.A. Sekeres, D. Rizzieri, J. Cortes, R. Redner, D. Steensma, G. Roboz, T. Moyo, M. McKeown, N. Waters, K. Stephens, E. di Tomaso, D.A. Roth, E. Stein
Journal: Annals of Oncology (2017)
Does treatment at a high volume center mitigate racial and ethnic disparities in ovarian cancer survival?
Authors: Renee A. Cowan, Jill Tseng, Vinat Palayekar, Renee L. Gennarelli, Nadeem Abu-Rustum, Dennis Chi, Kara C. Long-Roche, Carol L. Brown
Journal: Journal of Clinical Oncology (2017)

5584 Background: Population-based studies of women with advanced ovarian cancer report racial/ethnic disparities in access to high volume centers (HVCs), surgical outcomes after primary debulking surgery (PDS), and overall survival (OS). However, there is evidence that with equal utilization of expert ovarian cancer care, differences in survival dissipate. The objective of this study is to evaluate patients (pts) with advanced ovarian cancer who had PDS at a HVC to determine whether racial/ethnic disparities persist in surgical outcome and survival. Methods: With IRB approval, all pts with stages IIIB to IV high-grade ovarian cancer who underwent PDS from 1/2001-12/2013 were identified. Pts self-identified race/ethnicity as Non-Hispanic White (NHW), Non-Hispanic Black (NHB), Asian (A), or Hispanic (H) in the medical record. The main outcome measures were PDS &lt;1cm residual and OS. A Cox proportional hazards model was used to compare OS by race/ethnicity. Pt and clinical factors, including age, income, BRCA status, BMI, ASA, grade, carcinomatosis, bulky abdominal disease, were adjusted for in the multivariate analysis. Results: 963 pts were identified: 851 NHW (88%); 43 A (4%), 34 H (4%), 28 NHB (3%), 7 Other (0.7%). Asian pts were younger at diagnosis (p&lt;0.0001); there were no differences in other demographic or clinical characteristics among racial/ethnic groups. After adjusting for pt and clinical factors, the likelihood of PDS to residual &lt;1cm was similar among NHB and H compared to NHW pts; Asian pts were more likely than NHW to have &gt;1cm residual (OR 2.32, 95%CI 1.1-4.9, p=.03). Median OS was 55.1 mos (95%CI: 51.8-58.5) for the entire cohort. On both univariate and multivariate analysis, there was no disparity in OS among racial or ethnic groups (p=0.615). Conclusions: Racial and ethnic disparities in overall survival and surgical outcomes in women with advanced ovarian cancer can be reduced by treatment at a HVC. Additional research is needed to determine what factors are associated with receiving treatment at HVCs, and what interventions could increase the diversity of patients treated at HVCs.
Safety vs Efficacy of Lowering Blood Pressure
Authors: Jerzy Gasowski, Karolina Piotrowicz, Tomasz Grodzicki
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)
Authors: S. Fröhling, T.F. Barth, S. Gröschel, G. Folprecht, S. Richter, R. Mayer-Steinacker, M. Schultheiss, P. Möller, S. Bauer, J.T. Siveke, S. Dettmer, D. Richter, C. Heining, P. Horak, H. Glimm, D. Jäger, C. Von Kalle, R. Schlenk
Journal: Annals of Oncology (2017)
Community-based lung cancer screening of high-risk population with low-dose computed tomography in China
Authors: F. Qian, W. Yang, H. Wang, J. Teng, Y. Zhang, Q. Chen, J. Ye, J. Lou, R. Shi, L. Jiang, A. Gu, Y. Zhao, B. Jin, X. Zhang, J. Xu, Y. Lou, B. Han
Journal: Annals of Oncology (2017)
The Anterior Insular Cortex→Central Amygdala Glutamatergic Pathway Is Critical to Relapse after Contingency Management
Authors: Marco Venniro, Daniele Caprioli, Michelle Zhang, Leslie R. Whitaker, Shiliang Zhang, Brandon L. Warren, Carlo Cifani, Nathan J. Marchant, Ofer Yizhar, Jennifer M. Bossert, Cristiano Chiamulera, Marisela Morales, Yavin Shaham
Journal: Neuron (2017)

Despite decades of research on neurobiological mechanisms of psychostimulant addiction, the only effective treatment for many addicts is contingency management, a behavioral treatment that uses alternative non-drug reward to maintain abstinence. However, when contingency management is discontinued, most addicts relapse to drug use. The brain mechanisms underlying relapse after cessation of contingency management are largely unknown, and, until recently, an animal model of this human condition did not exist. Here we used a novel rat model, in which the availability of a mutually exclusive palatable food maintains prolonged voluntary abstinence from intravenous methamphetamine self-administration, to demonstrate that the activation of monosynaptic glutamatergic projections from anterior insular cortex to central amygdala is critical to relapse after the cessation of contingency management. We identified the anterior insular cortex-to-central amygdala projection as a new addiction- and motivation-related projection and a potential target for relapse prevention.
Cell-free (cf)DNA analysis identifies PIK3CA/AKT1 mutations associated with greater PFS improvement from the addition of ipatasertib (IPAT) to paclitaxel (P) in triple-negative breast cancer (TNBC)
Authors: M. Wongchenko, R. Dent, S-B. Kim, C. Saura, M. Oliveira, J. Baselga, A.V. Kapp, W.Y. Chan, S.M. Singel, D.J. Maslyar, S. Gendreau
Journal: Annals of Oncology (2017)
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
Authors: Maria Vittoria Dieci, Nina Radosevic-Robin, Susan Fineberg, Gert van den Eynden, Nils Ternes, Frederique Penault-Llorca, Giancarlo Pruneri, Timothy M. D’Alfonso, Sandra Demaria, Carlos Castaneda, Joselyn Sanchez, Sunil Badve, Stefan Michiels, Veerle Bossuyt, Federico Rojo, Baljit Singh, Torsten Nielsen, Giuseppe Viale, Seong-Rim Kim, Stephen Hewitt, Stephan Wienert, Sybille Loibl, David Rimm, Fraser Symmans, Carsten Denkert, Sylvia Adams, Sherene Loi, Roberto Salgado
Journal: Seminars in Cancer Biology (2017)

Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.
PSA doubling time (PSADT) and proximal PSA predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP): Implications for patient counseling and clinical trial design
Authors: M. Markowski, Y. Chen, Z. Feng, B. Trock, J. Cullen, D. Suzman, E. Antonarakis, C. Paller, M. Han, A. Partin, M. Eisenberger
Journal: Annals of Oncology (2017)
Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07)
Authors: Y. Kitagawa, Y. Doki, K. Kato, T. Ura, T. Kojima, T. Tsushima, S. Hironaka, H. Hara, T. Kudo, S. Iwasa, K. Muro, Y. Hamamoto, H. Yasui, K. Minashi, K. Yamaguchi, A. Ohtsu
Journal: Annals of Oncology (2017)
Sympathetic neuron–associated macrophages contribute to obesity by importing and metabolizing norepinephrine
Authors: Roksana M Pirzgalska, Elsa Seixas, Jason S Seidman, Verena M Link, Noelia Martínez Sánchez, Inês Mahú, Raquel Mendes, Vitka Gres, Nadiya Kubasova, Imogen Morris, Bernardo A Arús, Chelsea M Larabee, Miguel Vasques, Francisco Tortosa, Ana L Sousa, Sathyavathy Anandan, Erin Tranfield, Maureen K Hahn, Matteo Iannacone, Nathanael J Spann, Christopher K Glass, Ana I Domingos
Journal: Nature Medicine (2017)
Decision support system for the interpretation of multiplex genetic tests in gastrointestinal cancers
Authors: O. Fábián, B. Pálházi, D. Tihanyi, E. Várkondi, D. Mathiasz, C. Hegedüs, R. Schwáb, G. Bodoky, I. Vályi-Nagy, I. Peták
Journal: Annals of Oncology (2017)
North Japan multicenter phase II study of FOLFOX as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003): Analysis of tumor location
Authors: A. Ishiguro, S. Yuki, Y. Kawamoto, H. Nakatsumi, N. Takahashi, T. Shichinohe, T. Kusumi, I. Iwanaga, T. Miyagishima, K. Hatanaka, K. Oomori, M. Nakamura, N. Senmaru, K. Iwai, M. Koike, N. Sakamoto, A. Taketomi, S. Hirano, Y.M. Ito, Y. Komatsu
Journal: Annals of Oncology (2017)
KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma
Authors: A. Ribas, F.S. Hodi, D. Lawrence, V. Atkinson, S. Agarwal, M.S. Carlino, R. Fisher, G.V. Long, W.H. Miller, Y. Huang, B. Homet Moreno, N. Ibrahim, O. Hamid
Journal: Annals of Oncology (2017)
Factors influencing the use of thromboprophylaxis in cancer outpatients: CAT AXIS, a case-vignette study on clinical practice.
Authors: Florian Scotte, Ismail Elalamy, Didier Mayeur, Guy Meyer
Journal: Journal of Clinical Oncology (2017)

e18276 Background: Data on long-term venous thromboembolism (VTE) prophylaxis in cancer outpatients remain scarce. Our objective was to describe clinical practice and to identify factors influencing the use of thromboprophylaxis. Methods: CAT AXIS was a multicenter cross-sectional study based on the completion of physician-profile questionnaires and the assessment of 10 e-mailed credible clinical scenarios of lung, colon and breast cancer by each of participants using the case-vignettes validated method. Results: A total of 224 physicians participated allowing the completion and the analysis of 2,085 reviewed case vignettes corresponding to 765, 703 and 617 fictive clinical scenarios on lung, colon and breast cancers, respectively. The overall rate of thromboprophylaxis was 680/2085 (32.6%) among participants with a comparable proportion for the three types of cancer. Low-molecular-weight heparin (LMWH) was the most frequently used, by 92.7%, 93.8% and 83.9% of participants for lung, colon and breast cancer, respectively; treatment duration of ≥ 3 months was prescribed by 74.4% of participants. Multivariate analysis of factors influencing thromboprophylaxis based on patient’s characteristics is summarized in the table. Conclusions: In the absence of clear guidance, the use of thromboprophylaxis remains low and rather empiric even though the selection of LMWH by the majority of participants and treatment duration seems appropriate based on available data to date. ECOG index, metastatic malignancy, chemotherapy and history of thrombosis were significantly associated with the decision to use thromboprophylaxis in most situations. [Table: see text]
Foyers de légionellose associée aux voyages en France, septembre 2001-août 2003
Authors: B Decludt, C Campese, D Che, S Jarraud, J Etienne
Journal: Eurosurveillance (2004)

Les foyers de legionellose exigent une attention particuliere et sont detectes par le systeme national francais de surveillance et du reseau europeen EWGLINET. 
Entre septembre 2001 et aout 2003, 37 foyers ont ete identifies dans des sites touristiques en France : 27 hotels et 10 campings. La distribution des cas cliniques par foyer etait la suivante : 30 foyers de deux cas (81%), six foyers de trois cas (16%) et un foyer de quatre cas (3%), soit un total de 82 cas. Pour 36 des 37 foyers, des investigations environnementales ont ete realises par les autorites locales de sante et des prelevements d'eau ont ete recueillis pour 35 d'entre eux. Legionella pneumophila a ete trouve dans 16 sites (46%) a un niveau superieur a 103 cfu/litre. Dans tous les sites ou l'evaluation des risques a ete jugee inappropriee, des mesures de controle ont aussitot ete mises en place. Six hotels ont ete fermes immediatement suite a l'alerte. 
La comparaison des souches cliniques et environnementales, realisee par electrophorese en champ pulse (PFGE), a ete possible pour trois foyers et les profils genomiques obtenus etaient identiques. Au cours de ces deux annees de surveillance, les resultats indiquent qu'il existait un risque d'exposition a Legionella dans de nombreux sites. Ces resultats confirment l'importance du reseau europeen de surveillance et de la declaration rapide de tous les cas a EWGLINET.
Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective
Authors: A. Gomez de Liano Lista, A. Necchi, P. Lavaud, J. Carles Galceran, D. Castellano, A. Ravaud, I. Duran, N. van Dijk, P. Giannatempo, Y. Loriot, R. Morales Barrera, G. De Velasco Oria De Rueda, F. Lefort, G. Martínez Bernal, D. Raggi, M. Gross-Goupil, T. Powles, M. van der Heijden
Journal: Annals of Oncology (2017)
Abstract 16198: Ttc39b Deficiency Causes an Intestinal Lxr Activation Phenotype With Increased Expression Of Abca1 and HDL-Cholesterol Levels
Authors: Masahiro Koseki, Joanne Hsieh, Emi Yakushiji, Carrie Welch, Jahangir Iqbal, M.Mahmood Hussain, Shunichi Takiguchi, Shizuya Yamashita, Issei Komuro, Daniel J Rader, Alan R Tall
Journal: Circulation (2013)

TTC39B (T39) was identified in a GWAS as a novel gene influencing HDL cholesterol (HDL-c) levels. We have now verified increased HDL-c levels in T39-/- mice. On a chow diet HDL-c levels were significantly increased by 22% and there were increases in LXR protein but not mRNA, increased expression of ABCA1 mRNA and protein and increased secretion of HDL by small intestinal enterocytes. When mice were challenged with a high fat/high cholesterol/bile salt (Paigen) diet, there was a significant 42% increase in HDL-c and also decreased incorporation of dietary cholesterol and fat into chylomicrons and marked protection from steato-hepatitis; in addition to intestinal changes, there was increased LXR protein and induction of Abcg5/8 in liver. Ldlr-/-T39-/- mice on the Western diet showed increased HDL-c, decreased V/LDL cholesterol and decreased atherosclerosis. These studies show that T39 deficiency results in increased LXR primarily in enterocytes, beneficial lipoprotein changes and reduced atherosclerosis. Moreover, T39-/- mice are protected from fatty liver, indicating that T39 inhibition could be an effective strategy for reducing atherosclerosis and fatty liver.